Radiotherapy of the Primary Disease for Synchronous Metastatic Cancer: A Systematic Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 11

PMID 36497410

Authors

Youssef Ghannam

Adrien Laville

Youlia Kirova

Igor Latorzeff

Antonin Levy

Yuedan Zhou

Vincent Bourbonne

Affiliations

Soon will be listed here.

Abstract

In the case of synchronous metastatic disease, the local treatment of primary tumors by radiotherapy has long been reserved for palliative indications. The emergence of the concept of oligometastatic and oligopersistent diseases, the advent of new systemic therapies enabling longer overall survival with an enhanced quality of life, a better understanding of the biologic history of metastatic spread, and technical advances in radiation therapy are revolutionizing the management of patients with de novo metastatic cancer. The prognosis of these patients has been markedly improved and many studies have investigated the survival benefits from the local treatment of various primary tumors in cases of advanced disease at the time of diagnosis or in the case of oligopersistence. This article provides an update on the place of irradiation of the primary tumor in cancer with synchronous metastases, and discusses its interest through published or ongoing trials.

Citing Articles

Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach.

Kim N, Kim H, Park W, Cho W, Kim T, Im Y Radiat Oncol. 2023; 18(1):168.

PMID: 37821947 PMC: 10566115. DOI: 10.1186/s13014-023-02357-7.

References

Remon J, Steuer C, Ramalingam S, Felip E . Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018; 29(suppl_1):i20-i27. DOI: 10.1093/annonc/mdx704. View

Camidge D, Kim H, Ahn M, Yang J, Han J, Lee J . Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2027-2039. DOI: 10.1056/NEJMoa1810171. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

Gomez D, Blumenschein Jr G, Lee J, Hernandez M, Ye R, Camidge D . Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016; 17(12):1672-1682. PMC: 5143183. DOI: 10.1016/S1470-2045(16)30532-0. View

Arrieta O, Barron F, Maldonado F, Cabrera L, Corona-Cruz J, Blake M . Radical consolidative treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A phase II study. Lung Cancer. 2019; 130:67-75. DOI: 10.1016/j.lungcan.2019.02.006. View

Shaw A, Bauer T, de Marinis F, Felip E, Goto Y, Liu G . First-Line Lorlatinib or Crizotinib in Advanced -Positive Lung Cancer. N Engl J Med. 2020; 383(21):2018-2029. DOI: 10.1056/NEJMoa2027187. View

Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H . RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. Lung Cancer. 2015; 90(3):477-83. DOI: 10.1016/j.lungcan.2015.09.025. View

Parikh R, Cronin A, Kozono D, Oxnard G, Mak R, Jackman D . Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014; 89(4):880-7. DOI: 10.1016/j.ijrobp.2014.04.007. View

Fields R, Jeffe D, Trinkaus K, Zhang Q, Arthur C, Aft R . Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007; 14(12):3345-51. DOI: 10.1245/s10434-007-9527-0. View

10.

Nguyen D, Truong P, Alexander C, Walter C, Hayashi E, Christie J . Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?. Int J Radiat Oncol Biol Phys. 2012; 84(1):39-45. DOI: 10.1016/j.ijrobp.2011.11.046. View

11.

Borghaei H, Langer C, Paz-Ares L, Rodriguez-Abreu D, Halmos B, Garassino M . Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020; 126(22):4867-4877. PMC: 7692929. DOI: 10.1002/cncr.33142. View

12.

Giraud N, Abdiche S, Trouette R . Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer. Cancer Radiother. 2019; 23(4):346-354. DOI: 10.1016/j.canrad.2019.01.002. View

13.

Khan S, Stewart A, Morrow M . Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery. 2002; 132(4):620-6; discussion 626-7. DOI: 10.1067/msy.2002.127544. View

14.

Chan O, Lam K, Li J, Choi F, Wong C, Chang A . ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI. Lung Cancer. 2020; 142:41-46. DOI: 10.1016/j.lungcan.2020.02.002. View

15.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

16.

Topkan E, Akkus Yildirim B, Guler O, Parlak C, Pehlivan B, Selek U . Safety and palliative efficacy of single-dose 8-Gy reirradiation for painful local failure in patients with stage IV non-small cell lung cancer previously treated with radical chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2015; 91(4):774-80. DOI: 10.1016/j.ijrobp.2014.12.010. View

17.

Cho Y, Chang J, Rha K, Hong S, Choi Y, Ham W . Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?. PLoS One. 2016; 11(1):e0147191. PMC: 4726731. DOI: 10.1371/journal.pone.0147191. View

18.

Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C . Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis. Int J Cancer. 2017; 140(12):2805-2819. DOI: 10.1002/ijc.30691. View

19.

Kagawa Y, Furuta H, Uemura T, Watanabe N, Shimizu J, Horio Y . Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer. Cancer Sci. 2020; 111(12):4442-4452. PMC: 7734009. DOI: 10.1111/cas.14605. View

20.

Wang X, Zeng Z, Cai J, Xu P, Liang P, Luo Y . Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study. BMC Cancer. 2021; 21(1):482. PMC: 8086057. DOI: 10.1186/s12885-021-08228-2. View